DCK Antikörper
(2 Referenzen)-
- Target Alle DCK Antikörper anzeigen
- DCK (Deoxycytidine Kinase (DCK))
-
Reaktivität
- Human
-
Wirt
- Maus
-
Klonalität
- Monoklonal
-
Konjugat
- Dieser DCK Antikörper ist unkonjugiert
-
Applikation
- Western Blotting (WB), Immunohistochemistry (IHC), Flow Cytometry (FACS)
- Produktmerkmale
- Homo sapiens deoxycytidine kinase (DCK)
- Aufreinigung
- Purified from mouse ascites fluids by affinity chromatography
- Immunogen
- Full length human recombinant protein of human DCK (NP_000779) produced in HEK293T cell.
- Klon
- 16G6
- Isotyp
- IgG1
- Top Product
- Discover our top product DCK Primärantikörper
-
anti-Deoxycytidine Kinase (DCK) antibody
KO Validated DCK Reaktivität: Human WB, IHC, IF, IP, IHC (p), ICC Wirt: Kaninchen Polyclonal unconjugated
anti-Deoxycytidine Kinase (DCK) (Center) antibodyDCK Reaktivität: Human, Maus, Ratte WB, IF, IP, IHC (p), ICC Wirt: Kaninchen Polyclonal unconjugated
anti-Deoxycytidine Kinase (DCK) antibodyDCK Reaktivität: Human WB, IHC, IF, IHC (p), FACS Wirt: Maus Monoclonal 3F5 unconjugated
anti-Deoxycytidine Kinase (DCK) antibodyDCK Reaktivität: Human WB, IHC, IHC (p), FACS Wirt: Maus Monoclonal 16G6 unconjugated
anti-Deoxycytidine Kinase (DCK) (AA 171-200), (C-Term) antibodyDCK Reaktivität: Human, Maus WB, IF, IP, IHC (p) Wirt: Kaninchen Polyclonal RB05276 unconjugated
anti-Deoxycytidine Kinase (DCK) (AA 161-260) antibodyDCK Reaktivität: Human WB, ELISA, IF Wirt: Maus Monoclonal 1D12 unconjugated
anti-Deoxycytidine Kinase (DCK) (AA 1-260) antibodyDCK Reaktivität: Human WB, IHC, IF Wirt: Kaninchen Polyclonal unconjugated
anti-Deoxycytidine Kinase (DCK) (AA 1-260) antibodyDCK Reaktivität: Human WB, IP Wirt: Kaninchen Polyclonal unconjugated
anti-Deoxycytidine Kinase (DCK) (AA 161-260) antibodyDCK Reaktivität: Human WB, ELISA, IF Wirt: Maus Monoclonal 2F10 unconjugated
anti-Deoxycytidine Kinase (DCK) (AA 1-260) antibodyDCK Reaktivität: Human WB, IF Wirt: Maus Polyclonal unconjugated
-
- Applikationshinweise
- WB 1:500~2000, IHC 1:150, FLOW 1:100,
- Kommentare
-
The concentration of the product may vary between diferrent lots.
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Liquid
- Konzentration
- 0.5-1.0 mg/mL
- Buffer
- PBS (PH 7.3) containing 1 % BSA, 50 % glycerol and 0.02 % sodium azide.
- Konservierungsmittel
- Sodium azide
- Vorsichtsmaßnahmen
- This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Lagerung
- -20 °C
-
-
: "Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-κB activity." in: BMC cancer, Vol. 18, Issue 1, pp. 466, (2018) (PubMed).
: "Prognostic effect of hENT1, dCK and HuR expression by morphological type in periampullary adenocarcinoma, including pancreatic cancer." in: Acta oncologica (Stockholm, Sweden), Vol. 55, Issue 3, pp. 286-96, (2016) (PubMed).
-
: "Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-κB activity." in: BMC cancer, Vol. 18, Issue 1, pp. 466, (2018) (PubMed).
-
- Target
- DCK (Deoxycytidine Kinase (DCK))
- Andere Bezeichnung
- DCK (DCK Produkte)
- Hintergrund
- Deoxycytidine kinase (DCK) is required for the phosphorylation of several deoxyribonucleosides and their nucleoside analogs. Deficiency of DCK is associated with resistance to antiviral and anticancer chemotherapeutic agents. Conversely, increased deoxycytidine kinase activity is associated with increased activation of these compounds to cytotoxic nucleoside triphosphate derivatives. DCK is clinically important because of its relationship to drug resistance and sensitivity.
- Molekulargewicht
- 30.3 kDa
- Gen-ID
- 1633
- NCBI Accession
- NM_000788
- HGNC
- 1633
-
